Greenpro Capital Corp. (GRNQ): Nasdaq/NYSE listing notice — Greenpro Capital receives Nasdaq deficiency notice for bid price below $1.00

Greenpro Capital Corp.

Received Nasdaq letter on April 11, 2025 for non-compliance with minimum bid price rule.
Closing bid price below $1.00 for 30 consecutive business days (Feb 25 – Apr 10, 2025).
Has 180 calendar days, until October 8, 2025, to regain compliance by closing at $1.00+ for 10 days.
May consider a reverse stock split if needed; eligible for additional 180-day period if other listing standards met.
Common stock continues trading on Nasdaq under GRNQ; delisting possible if not cured.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.95

Greenpro Capital Corp. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5550(a)(2), 5810(c)(3)(A)

Exact text from the filing

April 11, 2025, Greenpro Capital Corp. (the “Company”) received a letter (the “Notice”) from the Nasdaq Stock Market LLC (the “NASDAQ”) notifying the Company that it is not in compliance with the minimum bid price requirement as set forth under NASDAQ Listing Rule 5550(a)(2) for continued listing of its common stock on the NASDAQ. Listing Rule 5550(a)(2) requires the registrant to maintain a minimum bid price of $1.00 per share for its securities listed on the NASDAQ, and Listing Rule 5810(c)(3)(A) provides that a failure to meet the minimum bid price requirement exists if the deficiency conti

View on SEC.gov

Browse all listing & compliance notices →

Greenpro Capital Corp. filing history →

Source: SEC EDGAR

accession 0001641172-25-003942

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.